Litcius/Paper detail

IL-33 as a Critical Cytokine for Inflammation and Fibrosis in Inflammatory Bowel Diseases and Pancreatitis

Masayuki Kurimoto, Tomohiro Watanabe, Ken Kamata, Kosuke Minaga, Masatoshi Kudo

2021Frontiers in Physiology29 citationsDOIOpen Access PDF

Abstract

IL-33 is a pleiotropic cytokine that promotes inflammation and fibrosis. IL-33 is produced by a broad range of cells, including antigen-presenting cells (APCs), epithelial cells, and fibroblasts. IL-33 produced by the innate immune cells has been shown to activate pro-inflammatory T helper type 1 (Th1) and T helper type 2 (Th2) responses. The intestinal barrier and tolerogenic immune responses against commensal microbiota contribute to the maintenance of gut immune homeostasis. Breakdown of tolerogenic responses against commensal microbiota as a result of intestinal barrier dysfunction underlies the immunopathogenesis of inflammatory bowel diseases (IBD) and pancreatitis. Recent studies have provided evidence that IL-33 is an innate immune cytokine that bridges adaptive Th1 and Th2 responses associated with IBD and pancreatitis. In this Mini Review, we discuss the pathogenic roles played by IL-33 in the development of IBD and pancreatitis and consider the potential of this cytokine to be a new therapeutic target.

Topics & Concepts

ImmunologyImmune systemCytokineInflammationInterleukin 22Innate lymphoid cellInflammatory bowel diseaseAcquired immune systemPancreatitisMedicineInnate immune systemGut floraBiologyInterleukinDiseasePathologyInternal medicineIL-33, ST2, and ILC PathwaysEosinophilic EsophagitisGastrointestinal disorders and treatments
IL-33 as a Critical Cytokine for Inflammation and Fibrosis in Inflammatory Bowel Diseases and Pancreatitis | Litcius